PL2134702T3 - Krystaliczne postacie 6-[2-(metylokarbamoilo)fenylosulfanylo]-3-e-[2-(pirydyn-2-ylo)etenylo]indazolu przydatne w leczeniu nienormalnego wzrostu komórek u ssaków - Google Patents

Krystaliczne postacie 6-[2-(metylokarbamoilo)fenylosulfanylo]-3-e-[2-(pirydyn-2-ylo)etenylo]indazolu przydatne w leczeniu nienormalnego wzrostu komórek u ssaków

Info

Publication number
PL2134702T3
PL2134702T3 PL08719405T PL08719405T PL2134702T3 PL 2134702 T3 PL2134702 T3 PL 2134702T3 PL 08719405 T PL08719405 T PL 08719405T PL 08719405 T PL08719405 T PL 08719405T PL 2134702 T3 PL2134702 T3 PL 2134702T3
Authority
PL
Poland
Prior art keywords
phenylsulfanyl
methylcarbamoyl
indazole
ethenyl
pyridin
Prior art date
Application number
PL08719405T
Other languages
English (en)
Other versions
PL2134702T5 (pl
Inventor
Anthony Michael Campeta
Brian Patrick Chekal
Robert William Mclaughling
Robert Alan Singer
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39831473&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2134702(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL2134702T3 publication Critical patent/PL2134702T3/pl
Publication of PL2134702T5 publication Critical patent/PL2134702T5/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL08719405.6T 2007-04-05 2008-03-25 Krystaliczne postacie 6-[2-(metylokarbamoilo)fenylosulfanylo]-3-e-[2-(pirydyn-2-ylo)etenylo]indazolu przydatne w leczeniu nienormalnego wzrostu komórek u ssaków PL2134702T5 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US91037907P 2007-04-05 2007-04-05
US97654607P 2007-10-01 2007-10-01
US3155408P 2008-02-26 2008-02-26
EP08719405.6A EP2134702B2 (en) 2007-04-05 2008-03-25 Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals
PCT/IB2008/000792 WO2008122858A2 (en) 2007-04-05 2008-03-25 Crystalline forms of 6- [2- (methylcarbamoyl) phenylsulfanyl] -3-e- [2- (pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals

Publications (2)

Publication Number Publication Date
PL2134702T3 true PL2134702T3 (pl) 2017-10-31
PL2134702T5 PL2134702T5 (pl) 2023-12-04

Family

ID=39831473

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08719405.6T PL2134702T5 (pl) 2007-04-05 2008-03-25 Krystaliczne postacie 6-[2-(metylokarbamoilo)fenylosulfanylo]-3-e-[2-(pirydyn-2-ylo)etenylo]indazolu przydatne w leczeniu nienormalnego wzrostu komórek u ssaków

Country Status (23)

Country Link
US (1) US8791140B2 (pl)
EP (4) EP4074702A1 (pl)
JP (2) JP5869197B2 (pl)
KR (1) KR101237588B1 (pl)
CN (2) CN103626739B (pl)
AR (1) AR065931A1 (pl)
AU (1) AU2008236444B2 (pl)
BR (1) BRPI0809471A2 (pl)
CA (1) CA2682859C (pl)
CY (1) CY1119119T1 (pl)
DK (1) DK2134702T4 (pl)
ES (2) ES2919351T3 (pl)
FI (1) FI2134702T4 (pl)
HK (1) HK1193405A1 (pl)
IL (1) IL201320A (pl)
MX (1) MX2009010761A (pl)
NZ (1) NZ580126A (pl)
PL (1) PL2134702T5 (pl)
PT (1) PT2134702T (pl)
RU (1) RU2518898C2 (pl)
SI (1) SI2134702T2 (pl)
TW (1) TWI481602B (pl)
WO (1) WO2008122858A2 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2134702T2 (sl) 2007-04-05 2023-12-29 Pfizer Products Inc. Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
JO3062B1 (ar) * 2010-10-05 2017-03-15 Lilly Co Eli R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
RU2014107767A (ru) 2011-09-30 2015-11-10 Пфайзер Инк. Фармацевтические композиции на основе n-метил-2-[3-((е)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]бензамида
MX2014005715A (es) 2011-11-11 2014-05-28 Pfizer N-metil-2-[3-((e)-2-piridin-2-il-vinil)-1h-indazol-6-ilsulfanil]- benzamida para el tratamiento de leucemia mielogenosa cronica.
WO2013105894A1 (en) 2012-01-13 2013-07-18 Xspray Microparticles Ab A method for producing stable, amorphous hybrid nanoparticles comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix- forming component.
US10098859B2 (en) 2012-09-05 2018-10-16 Amri Ssci, Llc Cocrystals of p-coumaric acid
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
CN104230886A (zh) * 2013-06-24 2014-12-24 南京华威医药科技开发有限公司 阿昔替尼新晶型
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
CN104650034A (zh) * 2013-11-22 2015-05-27 天津市汉康医药生物技术有限公司 一种稳定的阿西替尼化合物
CN105960415A (zh) 2014-02-04 2016-09-21 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
CN106458920B (zh) * 2014-03-31 2019-02-15 千寿制药株式会社 炔基吲唑衍生物及其用途
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
EP4279087A3 (en) 2015-02-26 2024-01-31 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
WO2016178150A1 (en) * 2015-05-05 2016-11-10 Shilpa Medicare Limited Novel polymorphs of axitinib
AU2016280003B2 (en) 2015-06-16 2021-09-16 Merck Patent Gmbh PD-L1 antagonist combination treatments
TW201808910A (zh) 2016-05-16 2018-03-16 帝人製藥股份有限公司 喹啉衍生物之結晶
KR20190062515A (ko) 2016-10-06 2019-06-05 화이자 인코포레이티드 암의 치료를 위한 아벨루맙의 투약 용법
CN106883212A (zh) * 2017-03-16 2017-06-23 合肥拓锐生物科技有限公司 一种xli晶型阿昔替尼的制备方法
US20220370606A1 (en) 2018-12-21 2022-11-24 Pfizer Inc. Combination Treatments Of Cancer Comprising A TLR Agonist
EA202193065A1 (ru) 2019-05-09 2022-03-02 Синтон Б.В. Фармацевтическая композиция, содержащая акситиниб
CN111187253B (zh) * 2020-01-09 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼新晶型
TW202202138A (zh) 2020-03-25 2022-01-16 美商歐克萊製藥公司 含有酪胺酸激酶抑制劑之眼用植入物
WO2022000265A1 (zh) * 2020-06-30 2022-01-06 天津理工大学 一种阿西替尼与戊二酸共晶及其制备方法
CN113943270B (zh) * 2020-07-15 2023-05-09 鲁南制药集团股份有限公司 一种阿昔替尼晶型
CN113943271B (zh) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 一种阿昔替尼晶型及其制备方法
CN114685437B (zh) * 2020-12-25 2022-12-09 鲁南制药集团股份有限公司 阿昔替尼与糖精共晶
CN114685436B (zh) * 2020-12-25 2022-12-02 鲁南制药集团股份有限公司 阿昔替尼糖精共晶水合物
CN114685431B (zh) * 2020-12-26 2022-11-29 鲁南制药集团股份有限公司 一种阿昔替尼柠檬酸盐晶型
CN114685435B (zh) * 2020-12-28 2023-01-31 鲁南制药集团股份有限公司 阿昔替尼马来酸盐晶型及其制备
CN114685434B (zh) * 2020-12-28 2023-06-16 鲁南制药集团股份有限公司 一种阿昔替尼与戊二酸共晶
CN114685432B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 阿昔替尼盐晶型及其制备方法
CN114685433B (zh) * 2020-12-28 2022-11-25 鲁南制药集团股份有限公司 一种阿昔替尼香草酸共晶盐及其制备
WO2023166418A2 (en) 2022-03-03 2023-09-07 Pfizer Inc. Multispecific antibodies and uses thereof
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
US7141581B2 (en) * 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
PE20010306A1 (es) * 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
CZ20022332A3 (cs) † 2000-01-07 2003-01-15 Transform Pharmaceuticals, Inc. Sestava vzorků
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
RU2341263C2 (ru) 2003-04-03 2008-12-20 Пфайзер Инк. Лекарственные формы, содержащие ag013736
CA2586176A1 (en) 2004-11-02 2006-05-11 Srinivasan Babu Methods for preparing indazole compounds
CN101094836A (zh) 2004-11-02 2007-12-26 辉瑞大药厂 制备吲唑化合物的方法
KR20070060145A (ko) 2004-11-02 2007-06-12 화이자 인코포레이티드 6-[2-(메틸카바모일)페닐설파닐]-3-ｅ-[2-(피리딘-2-일)에테닐]인다졸의 다형체 형태
CN101052633A (zh) 2004-11-02 2007-10-10 辉瑞大药厂 制备吲唑化合物的方法
MX2007005291A (es) * 2004-11-02 2007-07-19 Pfizer Metodos para preparar compuestos de indazol.
EP1885338A1 (en) 2005-05-19 2008-02-13 Pfizer, Inc. Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
SI2134702T2 (sl) * 2007-04-05 2023-12-29 Pfizer Products Inc. Kristalinične oblike 6-(2-(metilkarbamoil)fenilsulfanil)-3-E-(2-(piridin-2-il)etenil)indazola primerne za zdravljenje abnormalne rasti celic pri sesalcih
RU2014107767A (ru) † 2011-09-30 2015-11-10 Пфайзер Инк. Фармацевтические композиции на основе n-метил-2-[3-((е)-2-пиридин-2-ил-винил)-1н-индазол-6-илсульфанил]бензамида

Also Published As

Publication number Publication date
WO2008122858A8 (en) 2009-11-26
IL201320A0 (en) 2010-05-31
IL201320A (en) 2016-05-31
US8791140B2 (en) 2014-07-29
EP2134702B1 (en) 2017-05-31
EP2134702B2 (en) 2023-08-30
KR101237588B1 (ko) 2013-02-27
FI2134702T4 (fi) 2023-09-12
JP5869197B2 (ja) 2016-02-24
RU2518898C2 (ru) 2014-06-10
ES2634866T3 (es) 2017-09-29
PT2134702T (pt) 2017-07-31
CA2682859A1 (en) 2008-10-16
KR20090127949A (ko) 2009-12-14
JP2009019030A (ja) 2009-01-29
JP2014193900A (ja) 2014-10-09
WO2008122858A9 (en) 2009-06-18
SI2134702T2 (sl) 2023-12-29
WO2008122858A3 (en) 2009-05-07
TW200911781A (en) 2009-03-16
HK1193405A1 (zh) 2014-09-19
EP3252047A3 (en) 2018-08-15
EP4074702A1 (en) 2022-10-19
RU2009136593A (ru) 2011-04-10
CN103626739A (zh) 2014-03-12
AR065931A1 (es) 2009-07-08
EP2134702A2 (en) 2009-12-23
AU2008236444B2 (en) 2012-06-28
EP4249063A3 (en) 2024-03-13
CN103626739B (zh) 2015-12-30
BRPI0809471A2 (pt) 2014-09-09
US20100179329A1 (en) 2010-07-15
DK2134702T3 (en) 2017-08-21
ES2919351T3 (es) 2022-07-26
EP3252047B1 (en) 2022-05-11
AU2008236444A1 (en) 2008-10-16
TWI481602B (zh) 2015-04-21
CY1119119T1 (el) 2018-02-14
EP4249063A2 (en) 2023-09-27
SI2134702T1 (sl) 2017-07-31
PL2134702T5 (pl) 2023-12-04
MX2009010761A (es) 2009-10-28
ES2634866T5 (es) 2024-03-04
EP3252047A2 (en) 2017-12-06
WO2008122858A2 (en) 2008-10-16
CA2682859C (en) 2013-10-08
DK2134702T4 (da) 2023-09-25
NZ580126A (en) 2012-03-30
CN101679356A (zh) 2010-03-24

Similar Documents

Publication Publication Date Title
HK1193405A1 (zh) 適用於治療哺乳動物異常細胞生長的 甲基-氨甲酰基 苯基硫基 吡啶- -基 乙烯基 吲唑的晶型
TWI369205B (en) Sulfonyl amide derivatives for the treatment of abnormal cell growth
AP2008004488A0 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
PL2409727T3 (pl) Urządzenia elektroporacyjne do elektroporacji komórek u ssaków
GB0709420D0 (en) Machining process monitor
EP2182556A4 (en) PROCESS FOR MANUFACTURING A SOLAR CELL
EP2257986A4 (en) PROCESS FOR MANUFACTURING SOLAR CELLS
ZA201005208B (en) Process for the manufacture of solar cells
PL2321295T3 (pl) Pochodne 4-(pirydyn-4-ylo)-1H-[1,3,5]triazyn -2-onu jako inhibitory GSK2-beta do leczenia chorób degeneracyjnych
ZA200608394B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
SI2173891T1 (sl) Encimski proces za pridobivanje korteksolon-17-alfa-propionata v kristaliniäśni obliki iii
IL197695A0 (en) 3-amino-pyridine derivatives for the treatment of metabolic disorders
EP2154242A4 (en) METHOD FOR INDUCING MYOCARDIAL CELL DIFFERENTIATION USING G-CSF
GB0814443D0 (en) Process for cultivating cells
EP2092054A4 (en) METHOD FOR CONTROLLING THE GROWTH OF A CELL CULTURE
EP2424671A4 (en) METHOD FOR CONTROLLING TREATMENT CONDITIONS IN REFINERS
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
ZA200906990B (en) Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl) ethenyl] indazole suitable for the treatment of abnormal cell growth in mammals
EP2172562A4 (en) PROCESS FOR INTEGRATING NON-INVASIVE BACTERIA IN EUKARYOTIC CELLS
AU2008900382A0 (en) Method for treating B cell disorders
IL244553B (en) Altered placental cells
AU2007900771A0 (en) Method and Apparatus for the Treatment of Abnormal Cell Structures
IL192452A (en) A process for producing titanium salts
PL389673A1 (pl) Nowe pochodne 1-(2-pirydylo)-6-podstawione imidazo [1, 2-a][1, 3, 5] triazyny oraz sposób ich wytwarzania
ZA201000159B (en) Process for the production of substituted 5-quinolyl-oxazoles and pharmaceutically acceptable salts thereof